Scarica l'app Stockscreener
5.29
1.34%
0.07
Precedente Chiudi:
$5.22
Aprire:
$4.905
Volume 24 ore:
647.47K
Relative Volume:
0.45
Capitalizzazione di mercato:
$91.59M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+51.14%
1M Prestazione:
+478.14%
6M Prestazione:
+306.92%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$4.90
$5.8899
Intervallo di 1 settimana:
$3.52
$6.19
Portata 52W:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Nome
Citius Oncology Inc
Settore
Telefono
(908) 967-6677
Indirizzo
11 COMMERCE DRIVE, CRANFORD
Confronta CTOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
5.29 | 91.59M | 0 | 0 | 0 | 0.00 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.99 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.18 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.25 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.01 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-27 | Iniziato | Maxim Group | Buy |
Citius Oncology Inc Borsa (CTOR) Ultime notizie
Citius Oncology prepares for lymphoma treatment launch in 2025 By Investing.com - Investing.com Nigeria
Citius Oncology On Track to Launch Lymphir in US in H2 - MarketScreener
Citius Oncology prepares for lymphoma treatment launch in 2025 - Investing.com
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 - StreetInsider
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - The Victoria Advocate
Citadel Advisors LLC Makes New $26,000 Investment in Citius Oncology, Inc. (NASDAQ:CTOR) - Defense World
After Major Oncology Conference, All Eyes Turn to Industry Innovation - Cantech Letter
Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules - Longview News-Journal
Citius Pharmaceuticals Secures $15.8M Strategic Financing: LYMPHIR Commercial Launch Gets Green Light - Stock Titan
Citius Oncology partners with Cardinal Health for LYMPHIR distribution By Investing.com - Investing.com South Africa
Citius Oncology Enters Into Distribution Services Agreement With Cardinal Health - MarketScreener
Citius Oncology Signs US Distribution Deal With Cardinal Health for Lymphir - marketscreener.com
Cardinal Health (CAH) Partners with Citius Oncology for LYMPHIR Distribution | CAH Stock News - GuruFocus
Citius Oncology Inks Distribution Services Agreement With Cardinal Health For LYMPHIR - Nasdaq
Citius Oncology stock soars on distribution deal By Investing.com - Investing.com South Africa
Citius Oncology stock soars on distribution deal - Investing.com
Citius Oncology partners with Cardinal Health for LYMPHIR distribution - Investing.com
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health | CTXR Stock News - GuruFocus
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health - Yahoo Finance
Citius Oncology (NASDAQ:CTOR) Trading Up 3.4% – Here’s Why - Defense World
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Maxim Downgrades Citius Oncology to Hold From Buy - marketscreener.com
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Laun - GuruFocus
Citius Oncology (CTXR) Seeks Additional Capital for LYMPHIR Launch | CTXR Stock News - GuruFocus
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals Reports Critical Cash Position, Advances FDA-Approved LYMPHIR Launch Strategy - Stock Titan
Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - Yahoo Finance
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | CTXR Stock News - GuruFocus
Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - PR Newswire
Citius Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
US Stocks Dip As Investors Eye Trump's Tariff Announcements - Finimize
Citius Oncology IncReceives Nasdaq Notice For Bid Price Non-ComplianceSEC Filing - marketscreener.com
Citius Oncology (NASDAQ:CTOR) Trading 6.3% Higher – Still a Buy? - Defense World
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Longview News-Journal
Citius Oncology Inc (NASDAQ: CTOR) Is On The Fall - stocksregister.com
Citius Pharma secures $2 million in stock offering By Investing.com - Investing.com South Africa
Citius Pharma secures $2 million in stock offering - Investing.com India
Citius Oncology (NASDAQ:CTOR) Shares Up 39.8% – Still a Buy? - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
3 Penny Stocks to Watch Now, 4/1/25 - TipRanks
Why Citius Oncology Inc. Stock Spiked Over 7%? - timothysykes.com
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Citius Oncology Inc Azioni (CTOR) Dati Finanziari
Non sono disponibili dati finanziari per Citius Oncology Inc (CTOR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.54%
1.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):